Malarone

Atovaquone/proguanil, the active ingredient in Malarone, is an antimalarial presented as a tablet for oral use. It prevents and treats Plasmodium falciparum malaria in travelers, expatriates, and residents of endemic regions, covering both prophylaxis and acute uncomplicated infection. It is approved in the European Union and is commonly prescribed for short‑term travel regimens as well as for treatment courses lasting three days.

GNH USA supplies Malarone as a licensed, GDP‑compliant supplier serving hospitals, pharmacies and clinics worldwide, with full regulatory documentation.

Malarone is an antiprotozoal medication used in the prevention and treatment of malaria.

Pre‑exposure prophylaxis: prevents Plasmodium falciparum malaria in travelers to endemic areas. Post‑exposure prophylaxis: administered after potential mosquito exposure to reduce risk of infection. Acute uncomplicated malaria: treats confirmed Plasmodium falciparum infection in patients without severe disease.

Malarone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Abdominal pain - Headache - Vomiting

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic injury or elevated liver enzymes - Hemolytic anemia in patients with G6PD deficiency - Severe neutropenia or other blood dyscrasias

Before prescribing Malarone, clinicians should consider several precautionary measures to ensure safe use.

Pregnancy: Category B; use only when benefit outweighs potential risk. Breastfeeding: Caution advised; small amounts may be excreted in milk. Renal or hepatic impairment: Dose adjustment may be required; monitor function. G6PD deficiency: Risk of hemolysis; avoid or use with caution. Age considerations: Not recommended for children under 5 kg without specialist guidance. Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Malarone can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Rifampin, carbamazepine, phenytoin, or other strong CYP3A4 inducers: may markedly reduce atovaquone levels. - Protease inhibitors (e.g., ritonavir): can increase atovaquone concentrations and risk of toxicity. - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring. - Antiretroviral NNRTIs (e.g., efavirenz): may lower proguanil activation.

Moderate Interactions (Monitor Closely): - Antacids or sucralfate: can decrease absorption of atovaquone; separate dosing by at least 2 hours. - Statins (e.g., simvastatin): may increase risk of myopathy when combined. - Oral contraceptives: possible reduction in efficacy; consider additional contraceptive measures. - HIV protease inhibitors (e.g., lopinavir/ritonavir): may increase plasma levels; monitor for adverse effects.